Acetylcysteine

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2024 FINANCIAL RESULTS

Retrieved on: 
화요일, 4월 30, 2024
Pain, FDA, Omeprazole, Fungal infection, Gastroenterology, Lactulose, PIN, Skin, Clarithromycin, Nausea, Hyponatremia, Infection, Paracetamol, Amoxicillin, Cardiomyopathy, Duchenne muscular dystrophy, Helicobacter pylori, Vomiting, Patient, Idiopathic pulmonary fibrosis, Constipation, Granisetron, Multimedia, Health, Acetylcysteine, Fever, Ibuprofen

NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.

Key Points: 
  • NASHVILLE, Tenn., April 30, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, announced today that it will release its first quarter 2024 financial results and provide a company update after the market closes on Tuesday, May 7, 2024.
  • A conference call will be held on May 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on providing unique products that improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 2월 27, 2024
Fever, Ibuprofen, Clarithromycin, PIN, Lactulose, Multimedia, FDA, Acetylcysteine, Pain, Omeprazole, Granisetron, Amoxicillin, Idiopathic pulmonary fibrosis, Skin, Nausea, Vomiting, Constipation, Duchenne muscular dystrophy, Cardiomyopathy, Fungal infection, Hyponatremia, Paracetamol, Health, Patient, Helicobacter pylori, Infection, Gastroenterology

NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.

Key Points: 
  • NASHVILLE, Tenn., Feb. 27, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2023 financial results and provide a company update after the market closes on Tuesday, March 5, 2024.
  • A conference call will be held on March 5 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Alternatively, they can choose a "Call Me" option to have the system automatically call them at the start of the conference.

Capsulyte Unveils PREGAME: The Ultimate Solution for Party Recovery, Marking Its Debut at DC Fashion Week

Retrieved on: 
금요일, 2월 16, 2024
Glutathione, Acetaldehyde, DC Fashion Week, Metabolism, Acetylcysteine, Hangover, FDA, Food, Overalls, Silibinin, Silybum, NAC, Nausea, Thistle, Fatigue, Head, Headache, DHM, Oxidative stress, Disease, Dietary supplement

CRANBURY, N.J., Feb. 16, 2024 /PRNewswire/ -- Capitalizing on cutting-edge ingredients, Capsulyte's PREGAME has emerged as the most advanced product to aid in party recovery and address symptoms often associated with hangovers. As a significant milestone for the brand, Capsulyte has been invited to participate in the prestigious DC Fashion Week, a testament to the company's alignment with premium lifestyles and the fashion industry's elite. This invitation further underscores Capsulyte's commitment to excellence and positions PREGAME as the preferred choice for discerning individuals seeking to enjoy social occasions to the fullest, without the next-day regrets.

Key Points: 
  • As a significant milestone for the brand, Capsulyte has been invited to participate in the prestigious DC Fashion Week, a testament to the company's alignment with premium lifestyles and the fashion industry's elite.
  • Many individuals face the unpleasant reality of hangover symptoms such as headaches, fatigue, and nausea, resulting from alcohol consumption.
  • These effects can be primarily attributed to acetaldehyde, a toxic compound that is created when the liver metabolizes alcohol.
  • As the brand marks its presence at DC Fashion Week, Capsulyte is set to redefine the standards of social indulgence and wellness.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE THIRD QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 10월 31, 2023
Gastroenterology, Duchenne muscular dystrophy, Ibuprofen, FDA, Constipation, Clarithromycin, Granisetron, PIN, Hyponatremia, Lactulose, Vomiting, Omeprazole, Cardiomyopathy, Fungal infection, Skin, Infection, Health, Nausea, Multimedia, Helicobacter pylori, Fever, Acetylcysteine, Paracetamol, Pain, Patient, Amoxicillin, Idiopathic pulmonary fibrosis, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.

Key Points: 
  • NASHVILLE, Tenn., Oct. 31, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the third quarter 2023 financial results and provide a company update after the market closes on Tuesday, Nov. 7, 2023.
  • A conference call will be held on Nov. 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE SECOND QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 8월 1, 2023
Idiopathic pulmonary fibrosis, Lactulose, Gastroenterology, Fever, Acetylcysteine, Constipation, Hyponatremia, Multimedia, Duchenne muscular dystrophy, Pain, Vomiting, Helicobacter pylori, PIN, Patient, Paracetamol, Amoxicillin, Call Me, Omeprazole, Granisetron, Nausea, Fungal infection, Ibuprofen, Infection, Cardiomyopathy, FDA, Health, Clarithromycin, Skin, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.

Key Points: 
  • NASHVILLE, Tenn., Aug. 1, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the second quarter 2023 financial results and provide a company update after the market closes on Tuesday, Aug. 8, 2023.
  • A conference call will be held on Aug. 8 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

NEEDED ANNOUNCES NEW BREAKTHROUGH SUPPLEMENT, SPERM SUPPORT+

Retrieved on: 
수요일, 7월 19, 2023
Male, DNA, Pregnancy, Lycopene, OBGYN, Research, Coenzyme Q10, Acetylcysteine, Semen, Vitamin, Fertility, Oxidative stress, Men's health, Testosterone, LOS, Health, Probiotic, Environment, God Needs Men, Identity matrix, Antioxidant, Dietary supplement, Birth control

LOS ANGELES, July 19, 2023 /PRNewswire/ -- Needed, the breakthrough nutritional supplement brand creating new standards for perinatal wellness, today announced the launch of Sperm Support+. This product will help men maximize their role in successful, healthy conception. Male fertility factors in 40-50% of fertility struggles, warranting a needed conversation around the shared role of both partners in pregnancy outcomes. Sperm Support+ addresses male fertility with an expertly formulated, whole-body approach using targeted antioxidants, probiotics, and testosterone-supporting botanicals to boost sperm quality, quantity, and motility.

Key Points: 
  • With Studies Showing Male Sperm Counts Down 50+% Over the Last 50 Years,
    LOS ANGELES, July 19, 2023 /PRNewswire/ -- Needed, the breakthrough nutritional supplement brand creating new standards for perinatal wellness, today announced the launch of Sperm Support+ .
  • Sperm Support+ addresses male fertility with an expertly formulated, whole-body approach using targeted antioxidants, probiotics, and testosterone-supporting botanicals to boost sperm quality, quantity, and motility.
  • Needed Sperm Support+ is a whole-body approach to supporting men's fertility, combining clinically-studied ingredients to address multiple factors, including sperm health, hormone levels, and microbiome balance.
  • Sperm Support+ is available starting at $40 and as part of the comprehensive Needed Men's Fertility Support Plan.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE FIRST QUARTER 2023 FINANCIAL RESULTS

Retrieved on: 
화요일, 5월 2, 2023
Psoriatic arthritis, Lactulose, Gastroenterology, Fever, Acetylcysteine, Constipation, Methotrexate, Hyponatremia, Multimedia, Pain, Vomiting, Helicobacter pylori, PIN, Patient, Paracetamol, Amoxicillin, Systemic-onset juvenile idiopathic arthritis, Omeprazole, Nausea, Fungal infection, Ibuprofen, Infection, FDA, Health, Clarithromycin, Skin, Pharmaceutical industry, Vaccine, Online shopping

NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.

Key Points: 
  • NASHVILLE, Tenn., May 2, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release the first quarter 2023 financial results and provide a company update after the market closes on Tuesday, May 9, 2023.
  • A conference call will be held on May 9 at 4:30 p.m. Eastern Time, to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is a specialty pharmaceutical company focused on the delivery of high-quality, prescription brands designed to improve patient care.

Based on the Latest Scientific Research on NAC and Milk Thistle for Liver Health, a Physician Incubator for Nutraceutical Supplements, 1MD Nutrition, Releases Upleveled LiverMD® Formula

Retrieved on: 
월요일, 4월 3, 2023
Nutrition, Acetylcysteine, Liver disease, Thistle, Vitamin E, Prostate, Tocotrienol, NAC, Tocopherol, ALA, Disease, The Non-GMO Project, Glutathione, Liver, Health, Death, Dietary supplement, Silybum

IRVINE, Calif., April 3, 2023 /PRNewswire/ -- The physician incubator for the formulation of clinical-dosage natural supplements that address conditions from heart to liver, bone to gut, prostate and eye health, known for its short, clean ingredient labels, 1MD Nutrition is launching a new and improved version of LiverMD®. The reformulation developed by gastroenterologist, Dr. David Kahana, features a doubled daily dosage of Siliphos® milk thistle extract and clinically effective daily dosages of N-Acetylcysteine (NAC). LiverMD® with NAC and ALA became available to 1MD Nutrition customers this past Winter and rolls out to new customers this month. A dramatically improved version of the original formula that was nominated for a Nexty Award at the Natural Products Expo in 2020, LiverMD® with NAC and ALA retails for $49.99/bottle or a discounted $29.99/bottle for a 6-month supply.

Key Points: 
  • The reformulation developed by gastroenterologist, Dr. David Kahana, features a doubled daily dosage of Siliphos® milk thistle extract and clinically effective daily dosages of N-Acetylcysteine (NAC).
  • LiverMD® with NAC and ALA became available to 1MD Nutrition customers this past Winter and rolls out to new customers this month.
  • The new LiverMD® formula also now features 160 milligrams of the trademarked Siliphos® milk thistle extract; this volume now matches the clinically effective dose - shown in studies - to provide increased liver health benefits.
  • The liver is the largest of the internal solid organs and the metabolic center of the body.

CUMBERLAND PHARMACEUTICALS TO ANNOUNCE ANNUAL 2022 FINANCIAL RESULTS

Retrieved on: 
화요일, 2월 28, 2023
Skin, Infection, Helicobacter pylori, Pain, Rheumatology, Fever, Vomiting, Gastroenterology, Acetylcysteine, FDA, Patient, Paracetamol, Methotrexate, Systemic-onset juvenile idiopathic arthritis, Nausea, Health, Lactulose, PIN, Multimedia, Amoxicillin, Psoriatic arthritis, Omeprazole, Hyponatremia, Clarithromycin, Constipation, Fungal infection, Ibuprofen, Vaccine, Pharmaceutical industry, Online shopping

NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.

Key Points: 
  • NASHVILLE, Tenn., Feb. 28, 2023 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceuticals company, announced today that it will release its annual 2022 financial results and provide a company update after the market closes on Tuesday, March 7, 2023.
  • A conference call will be held March 7 at 4:30 p.m. Eastern Time to discuss the results.
  • Once registered, participants can dial in from their phone using a dial-in and PIN number that will be provided to them.
  • Cumberland Pharmaceuticals is the largest biopharmaceutical company founded and headquartered in the Mid-South and is focused on the delivery of high-quality, prescription brands designed to improve patient care.

Jarrow Formulas® Offers Vegetarian N-A-C Antioxidant Supplement

Retrieved on: 
금요일, 12월 9, 2022
Mineral, Heart, Food, Glutathione, Soybean, Metabolism, Research, Liver, The Non-GMO Project, Vitamin, Disease, Good manufacturing practice, Multimedia, Acetylcysteine, Amazon, Brain, Food and Drug Administration, Jarrow, CGMP, Sulfur, Dietary supplement

SANTA FE SPRINGS, Calif., Dec. 9, 2022 /PRNewswire/ -- Jarrow Formulas®, the #1 probiotic brand for customer satisfaction, announced the launch of N-A-C, featuring 500mg of N-Acetyl-L-Cysteine in a vegetarian capsule form. The latest product offering is a powerful antioxidant amino acid, as well as a precursor in the body to the critical antioxidant glutathione – one of the body's most important and abundant antioxidant and detoxification agents.* More specifically, N-Acetyl-L-Cysteine supplies readily available L-cysteine, which acts as an antioxidant itself or as a precursor to glutathione.

Key Points: 
  • SANTA FE SPRINGS, Calif., Dec. 9, 2022 /PRNewswire/ -- Jarrow Formulas , the #1 probiotic brand for customer satisfaction, announced the launch of N-A-C , featuring 500mg of N-Acetyl-L-Cysteine in a vegetarian capsule form.
  • The latest product offering is a powerful antioxidant amino acid, as well as a precursor in the body to the critical antioxidant glutathione one of the body's most important and abundant antioxidant and detoxification agents.
  • * More specifically, N-Acetyl-L-Cysteine supplies readily available L-cysteine, which acts as an antioxidant itself or as a precursor to glutathione.
  • "At Jarrow, we have been paying close attention to a number of independent clinical studies which underscoretheeffectivenessofN-A-Canditsability tosupportbetter health,"saidHanan Wajih, Chief Marketing Officer of Jarrow Formulas.